Donor lymphocyte infusion (DLI) can restore remission in a high percentage of patients with chronic myeloid leukaemia (CML) who relapse after allogeneic stem cell transplant (SCT). Subsequent relapses after a DLIinduced remission do occur and the optimal management of these patients is not defined. A retrospective study of the practice of UK transplant centres was conducted. In all, 13 patients from seven centres were identified: all were treated for relapse post allogeneic SCT with DLI and achieved either a complete cytogenetic (n ¼ 5) or molecular (n ¼ 8) remission. All patients subsequently had a second relapse, at molecular (n ¼ 7), cytogenetic (n ¼ 4) and haematological (n ¼ 2) levels. Further DLI was used in the treatment of 11 patients, imatinib mesylate in three and chemotherapy in two. The two patients with haematological relapse died of blastic disease. The remaining 11 patients achieved either a complete cytogenetic (n ¼ 2) or molecular (n ¼ 9) remission. Nine patients remain in molecular remission at a median follow-up of 29 months, seven of whom had received DLI alone as treatment for second relapse, one DLI plus imatinib and one imatinib alone. Toxicity following DLI for second relapse was low. Longer follow-up will be required to see if these second DLI-induced remissions will be durable.
Summary:
Donor lymphocyte infusion (DLI) can restore remission in a high percentage of patients with chronic myeloid leukaemia (CML) who relapse after allogeneic stem cell transplant (SCT). Subsequent relapses after a DLIinduced remission do occur and the optimal management of these patients is not defined. A retrospective study of the practice of UK transplant centres was conducted. In all, 13 patients from seven centres were identified: all were treated for relapse post allogeneic SCT with DLI and achieved either a complete cytogenetic (n ¼ 5) or molecular (n ¼ 8) remission. All patients subsequently had a second relapse, at molecular (n ¼ 7), cytogenetic (n ¼ 4) and haematological (n ¼ 2) levels. Further DLI was used in the treatment of 11 patients, imatinib mesylate in three and chemotherapy in two. The two patients with haematological relapse died of blastic disease. The remaining 11 patients achieved either a complete cytogenetic (n ¼ 2) or molecular (n ¼ 9) remission. Nine patients remain in molecular remission at a median follow-up of 29 months, seven of whom had received DLI alone as treatment for second relapse, one DLI plus imatinib and one imatinib alone. Toxicity following DLI for second relapse was low. Longer follow-up will be required to see if these second DLI-induced remissions will be durable. Bone Marrow Transplantation (2005) 36, 1065-1069. doi:10.1038/sj.bmt.1705180; published online 10 October 2005 Keywords: chronic myeloid leukaemia; stem cell transplantation; donor lymphocyte infusion; relapse; imatinib mesylate Allogeneic haemopoietic stem cell transplantation (SCT) is currently the only strategy proven to cure patients with chronic myeloid leukaemia (CML). One of the major causes of treatment failure following allogeneic SCT is leukaemic relapse. This occurs in 10-30% of patients allografted in chronic phase with unmanipulated haematopoietic stem cells, but is considerably higher when T cell depletion strategies are used or when the transplant is performed in patients with advanced phase CML. 1, 2 Numerous studies have confirmed the efficacy of infusion of lymphocytes from the original stem cell donor (donor lymphocyte infusion, DLI) in restoring remission in a high percentage of patients with CML in relapse after allografting. 3, 4 This approach has become the treatment of choice in many transplant centres. Molecular and cytogenetic relapses may be more responsive to DLI than haematological relapse, with chronic phase responding better than advanced phase disease.
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Graft-versus-host disease (GVHD) and marrow aplasia remain the two most important complications of DLI, the latter occurring virtually only in patients treated in haematological relapse. Durable complete remissions can be achieved in the majority of patients with molecular and cytogenetic relapses or in chronic phase disease. Subsequent relapses, although uncommon, have been described. 4, 6 The optimal management of patients relapsing after a DLI-induced remission is not defined and there are few data on the efficacy of the treatment strategies used, or the long-term follow-up of this group. Since there is a lack of information in the literature to date and the emerging role of imatinib mesylate in CML management, a retrospective study was conducted on behalf of the BSBMT to assess the practice of UK transplant centres
Patients and methods
In January 2003, data were collected by means of a standardised proforma sent to 21 UK adult allogeneic transplant centres identified through the British Society of Blood and Marrow Transplantation. Eligible patients were defined as those having received DLI for treatment of relapse after an allogeneic SCT for Philadelphia (Ph) chromosome-positive CML, attained a DLI-induced remission (cytogenetic or molecular), and subsequently had a second relapse. Data were submitted by all 21 centres surveyed: 14 centres reported having no eligible patients. In all, 13 patients from seven centres, who underwent allogeneic SCT between April 1990 and September 2000, were identified as fulfilling the eligiblility criteria.
Definitions of relapse
The 13 patients identified satisfied criteria for molecular, cytogenetic or haematological relapse at the time when treatment with DLI was initiated and subsequently at second relapse following a DLI-induced remission. Molecular relapse was defined as the detection of BCR-ABL transcripts by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in two consecutive samples over a minimum of 4 weeks. 7, 8 Cytogenetic relapse was defined as the presence of one or more Ph-positive marrow metaphases without evidence of haematological relapse. Haematological relapse was diagnosed in the presence of peripheral blood leukocytosis accompanied by a hypercellular bone marrow with Ph chromosome-positivity on cytogenetic analysis. The phase of CML was classified in accordance with criteria proposed by the International Bone Marrow Transplantation Registry. 9 In a number of patients serial molecular data were not available, and therefore, relapse was recognised first by cytogenetic or haematological criteria.
Definitions of remission post DLI
Complete cytogenetic remission (CCR) required the absence of Ph chromosome by standard cytogenetic analysis of bone marrow metaphases. Molecular remission was defined as the absence of detectable BCR-ABL transcripts by RT-PCR analysis of peripheral blood on two consecutive occasions at least 4 weeks apart.
Donor lymphocyte infusion
The method of administration of DLI was not uniform between centres. The total cell dose ( Â 10 6 CD3 cells/kg) is stated.
The presence of acute and chronic GVHD occurring either prior to relapse or after DLI was graded according to standard clinical criteria. 10, 11 Myelosuppression due to graft hypoplasia after DLI was defined as a cytopenia (neutrophils o0.5 Â 10 9 /l or platelets o20 Â 10 9 /l) unrelated to disease progression or chemotherapy.
Results

Patient characteristics and transplant procedure
A total of 13 patients with Ph-positive CML from seven transplant centres were identified as fulfilling the eligibility criteria. The original allogeneic SCTs were performed between April 1990 and September 2000. At that time, 11 patients were in chronic phase, and two were in second chronic phase of CML. Both patients in second chronic phase had received previous transplants from the same respective donor and had relapsed with haematological disease. Seven patients received bone marrow and one patient peripheral blood stem cells (PBSC) from their respective HLA-identical siblings. Four patients received cells from volunteer unrelated donors (VUDs), three receiving bone marrow and one PBSC. All were serologically matched at the HLA A, B and DR loci. One patient received HLA identical bone marrow cells from a parent who was HLA-identical at both MHC class I and class II loci and had a non nonreactive cytotoxic T lymphocyte precursor (CTLp) assay was performed. The median age at transplantation was 35 years (range 23-55 years) and the male to female ratio 2:1. In all, 10 patients were conditioned with cyclophosphamide and total body irradiation (TBI). Two patients received busulphan and cyclophosphamide and one patient busulphan alone. Cyclosporine and short course methotrexate were used as GVHD prophylaxis in 10 patients and cyclosporine alone in three. In addition, all the VUD transplant recipients and three recipients of sibling transplants (patient nos. 5, 8, 13) received additional T cell depletion in the form of Campath 1G, 1H or 1M given either intravenously or by in vitro treatment of donor cells. Post SCT, four patients developed grade I acute GVHD and three grade II. Five patients had chronic GVHD, this being limited in four and extensive (skin, liver and lung) in one patient.
Management of relapse post allogeneic SCT
The details of the management of the first and subsequent relapses in the 13 patients in this study are shown in Tables  1 and 2 . The median time from allogeneic SCT to first relapse was 12 months (range 4-53 months). The diagnosis of relapse was molecular (n ¼ 4), cytogenetic (n ¼ 7) or haematological (n ¼ 2) as defined above. The median time to first relapse was slightly shorter in the patients who received Campath (n ¼ 7) compared to those who did not (n ¼ 6) (12 months vs 19.5 months, P ¼ NS). Immunosuppression was reduced and stopped in all patients at diagnosis of relapse. All patients received DLI as treatment for first relapse, this being administered between December 1994 and December 2001. One patient received bulk dose DLI (patient no. 11, 100 Â 10 6 CD3 cells/kg). All other patients received DLI according to local institutional protocols. The median interval from diagnosis of leukaemic relapse to DLI was 2 months (range 1-19 months). During this interval, one patient progressed from molecular relapse to haematological relapse in accelerated phase (patient no. 1). Thus at the time of DLI, three patients were in molecular relapse, seven in cytogenetic relapse and three in haematological relapse (2 CP, 1 AP).
The median total dose of DLI administered for all patients was 10 Â 10 6 CD3 cells/kg (range 1-100 Â 10 6 CD3 cells/kg). In patients receiving DLI from an unrelated donor, the median total dose administered was 6.5 Â 10 6 CD3 cells/kg (range 1-50 Â 10 6 CD3 cells/kg), whereas in those patients with a sibling or parent donor, the median total dose was higher at 20 Â 10 6 CD3 cells/kg (range 10-100 Â 10 6 CD3 cells/kg). In addition to DLI, both patients in chronic phase received hydroxyurea; the patient in accelerated phase received hydroxyurea and imatinib mesylate 800 mg daily. One patient (patient no. 7) received interferon-a with DLI. All patients attained a complete cytogenetic remission (CCR) in a median time of 6.5 months (range 2-34 months). Molecular remission status was assessed in eight of 13 patients: all were in molecular remission with a median time to attainment of 12.5 months (range 4-26 months). There was no difference between the Campath and nonCampath groups in the level of remission obtained (4/7 molecular vs 4/6 molecular, P ¼ NS). There were no cases of marrow hypoplasia seen. Acute GVHD I grade was seen in one patient, this patient having also received interferon. Acute grade III GVHD occurred in the patient who received 100 Â 10 6 CD3 cells/kg. The remaining 11 patients had no acute GVHD. Limited chronic GVHD was seen in one patient only.
Management of second relapse
All patients subsequently relapsed after attaining a DLIinduced remission. The median interval from DLI induced remission to second relapse was 9 months (3-58 months). The median duration of the first remission was shorter in the patients who had received Campath, although again this difference was not statistically significant (5 months vs 14.5months, P ¼ NS). At the time of subsequent treatment, the relapse was based on molecular (n ¼ 7), cytogenetic (n ¼ 4) or haematological (n ¼ 2) criteria. Of the two haematological relapses, one patient was in accelerated phase and one in myeloid blast crisis. Subsequent relapses were treated between July 1998 and March 2003, and four patients were treated at a time when imatinib mesylate had Treatment of relapsed CML M Cummins et al become widely available. DLI was used to treat 11 of these patients. In eight patients it was used alone (four molecular relapses, four cytogenetic relapses), in two patients it was combined with imatinib mesylate (both molecular relapse) and in the 11th patient it was combined with chemotherapy for accelerated phase CML. One patient in molecular relapse was treated with imatinib mesylate alone. The final patient received intensive chemotherapy for myeloid blast crisis. Both patients with haematological relapse died of blastic disease at 3 and 6 months post diagnosis without attaining a second remission. Of the remaining 11 patients, the four in cytogenetic relapse achieved CCR with DLI alone at a median of 3 months (range 3-7 months). Three of the four achieved a molecular remission at a median of 3 months (range 3-8 months). Of the seven patients in molecular relapse, four were treated with DLI alone and all achieved a molecular remission after a median of six months (range 3-17 months). Two patients with molecular relapse were treated with a combination of DLI and imatinib mesylate. One achieved a molecular remission after 8 months treatment: the other patient failed to achieve a molecular remission but remained in CCR, with reducing numbers of BCR-ABL transcripts. The final patient with molecular relapse was treated with imatinib mesylate alone and attained a molecular remission after four months treatment. There was no difference between the Campath and nonCampath groups in the level of the second remission that was obtained (data not shown).
The median total dose of DLI administered to the 11 patients treated with DLI for second relapse was 50 Â 10 6 CD3 cells/kg (range 10-100 Â 10 6 CD3 cells/kg). In patients receiving DLI from an unrelated donor (n ¼ 3), the median total dose administered was 10 Â 10 6 CD3 cells/kg (range 10-100 Â 10 6 CD3 cells/kg), whereas in those patients with a sibling or parent donor (n ¼ 8), the median total dose was 50 Â 10 6 CD3 cells/kg (range 10-100 Â 10 6 CD3 cells/kg). No marrow hypoplasia or GVHD was seen following DLI for second relapse.
All nine patients attaining a molecular remission remain in molecular remission at a median follow-up of 29 months (range 5-53 months). Of the three patients treated with imatinib mesylate, two have discontinued treatment: one due to severe gastric erosions (800 mg daily þ DLI) and the second electively after one year of molecular remission with imatinib alone. Both remain in molecular remission with a median duration of 9 months (6 and 12 months, respectively). The third patient remains on imatinib mesylate and has persistent but decreasing levels of BCR-ABL transcripts after 4 months treatment. The patient in cytogenetic relapse who failed to attain molecular remission (patient 11) had a haematological relapse (CP) 12 months after achieving CCR. She has received further DLI at a total dose of 330 Â 10 6 CD3 cells/kg, with haematological response and complicated by grade II liver GVHD.
Discussion
In this retrospective study, identification of treatment strategies used for patients relapsing after DLI, the efficacy of these treatments and the medium term outcome of this patient group were assessed. DLI was used to treat 11 out of the 13 patients at second relapse, either alone (n ¼ 8) or in combination with imatinib mesylate (n ¼ 2) or chemotherapy (n ¼ 1). In patients not in accelerated phase or blast crisis, DLI was effective in reinducing a second remission, this being a molecular remission in eight and a complete cytogenetic remission in two. The majority of the DLI were given according to an escalating protocol and a higher median dose of DLI was used to treat the second relapse compared to the first relapse. Toxicity of DLI, as assessed by occurrence of GVHD and Karnofsky score, was minimal, even in patients with a history of GVHD post SCT. At last follow-up, none of the patients who achieved a second molecular remission had relapsed, an observation in accord with the suggestion that attainment of molecular remission may be predictive of a durable remission. 4 In addition, remission after the second has been longer than remission after first DLI in seven patients. Of the two patients failing to achieve molecular remissions, one has subsequently relapsed and one remains in CCR. It is not known whether these remissions are durable due to the leukaemia being eradicated or because donor T cells are able to produce active immunosurveillance over the leukaemia. Similarly, relapse following a DLI-induced remission may be a result of T cell anergy induced by tumour cells, which may also account for DLI failures in advanced phase CML. Clearly, more prolonged follow-up of this patient cohort will be of interest, as subsequent relapses may occur late, as demonstrated by three of the patients, in whom the second relapse occurred more than 3 years after earlier DLI-induced remission.
The introduction of the novel tyrosine kinase inhibitor, imatinib mesylate, into clinical practice has increased the therapeutic options for all patients with CML. Imatinib mesylate has been widely used to restore remission in patients relapsing after allogeneic SCT. [12] [13] [14] These series have reported patients with predominantly haematologicalal relapse post allogeneic SCT, some of whom also received DLI either prior to or concurrently with imatinib. Kantarjian et al 12 reported a series of 28 patients who achieved a complete haematological response rate of 74% and cytogenetic response rate of 58%, with CCR in 35%. Four out of 28 patients achieved a complete molecular response. In a study on behalf of the European Group for Blood and Marrow Transplantation (EBMT), Olavarria et al 13 reported on 128 patients treated with imatinib, 50 of whom had failed treatment with donor lymphocyte infusions. The overall CCR obtained was 54% (58% in CP, 48% in AP and 22% in BC). Molecular remission was achieved in 25 patients (26%), of whom 21 were in CP or AP. Remissions appear durable, at least in patients in chronic phase, although further follow-up is required. The results for AP patients were particularly encouraging and appeared superior to those achieved with other treatment modalities, including DLI. Responses in BC patients were short lived and the poor prognosis of these patients was not significantly altered by the use of imatinib in this study. DeAngelo et al 14 treated 10 patients in chronic phase relapse with imatinib only and reported a CCR of nine of 10 patients with molecular remission in seven out of nine.
The experience of treatment of molecular relapse postallograft with imatinib is more limited. Conneally et al 15 reported molecular remission in four out of five patients treated with imatinib alone for molecular relapse post allograft. The molecular response rate in these reports appears higher than that seen in the nontransplant setting, where less than 10% of patients achieve a molecular remission. 16 It is possible that imatinib given in relapse post SCT reduces the level of residual leukaemia to a minimum, with graft-versus-leukaemia effect being responsible for eradication of CML below level of detection by current PCR techniques. Whether imatinib alters the graft-versusleukaemia effect of DLI is not known and it is unclear if giving the two therapies concurrently produces a better outcome. It is possible that the combination of DLI and imatinib may be beneficial in some cases, possibly reducing the need for higher doses of DLI or controlling disease whilst waiting for a graft versus leukaemia effect. However, combining therapies may create uncertainty as to which therapy has been effective and introduces difficult management decisions concerning future withdrawal of imatinib. These issues require further study.
In summary, this study shows that DLI for second relapse after allogeneic SCT for CML is associated with a good outcome in patients who are not in advanced phase disease. DLI was well tolerated and associated with minimal toxicity. If a donor is not available or if the patient is not suitable for DLI, imatinib mesylate may lead to cytogenetic or molecular remissions. However, prolonged follow-up is needed to determine if these responses are durable and establish the precise role of imatinib in relapse post SCT.
